![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ANXA2R |
Gene summary for ANXA2R |
![]() |
Gene information | Species | Human | Gene symbol | ANXA2R | Gene ID | 389289 |
Gene name | annexin A2 receptor | |
Gene Alias | AX2R | |
Cytomap | 5p12 | |
Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q3ZCQ2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
389289 | ANXA2R | LP17 | Human | Oral cavity | LP | 2.97e-02 | 3.54e-01 | 0.2349 |
389289 | ANXA2R | SYSMH1 | Human | Oral cavity | OSCC | 9.09e-08 | 1.88e-01 | 0.1127 |
389289 | ANXA2R | SYSMH2 | Human | Oral cavity | OSCC | 5.98e-03 | 1.19e-01 | 0.2326 |
Page: 1 2 3 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANXA2R | SNV | Missense_Mutation | c.197G>A | p.Gly66Glu | p.G66E | Q3ZCQ2 | protein_coding | tolerated(0.26) | benign(0.075) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
ANXA2R | SNV | Missense_Mutation | c.121T>C | p.Tyr41His | p.Y41H | Q3ZCQ2 | protein_coding | deleterious(0) | possibly_damaging(0.662) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
ANXA2R | SNV | Missense_Mutation | c.371N>T | p.Ser124Ile | p.S124I | Q3ZCQ2 | protein_coding | tolerated(0.32) | benign(0.01) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ANXA2R | SNV | Missense_Mutation | novel | c.293N>C | p.Lys98Thr | p.K98T | Q3ZCQ2 | protein_coding | tolerated(0.34) | possibly_damaging(0.451) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
ANXA2R | SNV | Missense_Mutation | novel | c.275N>T | p.Ser92Ile | p.S92I | Q3ZCQ2 | protein_coding | tolerated(0.42) | benign(0.01) | TCGA-AX-A1CF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxifen | PD |
ANXA2R | SNV | Missense_Mutation | novel | c.103C>T | p.Pro35Ser | p.P35S | Q3ZCQ2 | protein_coding | deleterious(0.04) | possibly_damaging(0.737) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANXA2R | SNV | Missense_Mutation | novel | c.40N>A | p.Asp14Asn | p.D14N | Q3ZCQ2 | protein_coding | tolerated(0.27) | benign(0.32) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
ANXA2R | SNV | Missense_Mutation | novel | c.104N>G | p.Pro35Arg | p.P35R | Q3ZCQ2 | protein_coding | tolerated(0.09) | possibly_damaging(0.597) | TCGA-DD-AACP-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ANXA2R | SNV | Missense_Mutation | novel | c.143C>T | p.Ser48Leu | p.S48L | Q3ZCQ2 | protein_coding | tolerated(0.08) | benign(0.204) | TCGA-MP-A4TI-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
ANXA2R | SNV | Missense_Mutation | rs754645658 | c.514N>T | p.Val172Phe | p.V172F | Q3ZCQ2 | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.859) | TCGA-NJ-A4YQ-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |